Myopia Control: a Comparison Study Between Atropine and MiSight
Recruiting
Phase 2Interventional Study
Myopia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
5 – 12
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
348 (estimated)
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago · Other
Who this trial is looking for
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This research project aims to provide additional knowledge of pharmacological and optical methods of myopia control and to gain a better understanding of the biometry of the pediatric eye, which contributes to the onset and progression of myopia. As a result, this study will improving our best practices for myopia control in pediatric patients.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Children age of 5-12 years old at their baseline exam
* Children with a spherical equivalent refractive error of +0.50D (minimal hyperopia) to -7.50 D (high myopia)
* Gestational age ≥ 32 weeks.
* Birth weight \>1500g.
Exclusion Criteria:
* Current or previous form of myopia…
Inclusion Criteria:
* Children age of 5-12 years old at their baseline exam
* Children with a spherical equivalent refractive error of +0.50D (minimal hyperopia) to -7.50 D (high myopia)
* Gestational age ≥ 32 weeks.
* Birth weight \>1500g.
Exclusion Criteria:
* Current or previous form of myopia control
* Current or previous use of bifocal, progressive- addition lenses, or multifocal contact lenses
* Known atropine allergy or contact lens intolerance (allergy to only one can still allow enrollment in the other group)
* Abnormality of cornea, lens, central retina, iris, or ciliary body
* Current or prior history of manifest strabismus, amblyopia, or nystagmus
* Current or previous myopia treatment with atropine, pirenzepine or another anti-muscarinic agent.
* Current or previous use of bifocals, progressive-addition lenses, or multi-focal contact lenses.
* Current or previous use of orthoK, rigid gas permeable, or other contact lenses being used to reduce myopia progression.
* Abnormality of the cornea, lens, central retina, iris, or ciliary body.
* Prior eyelid, strabismus, intraocular, or refractive surgery.
* Down syndrome or cerebral palsy.
* Diseases known to affect accommodation, vergence, or ocular motility (e.g., multiple sclerosis, Grave's disease, myasthenia gravis, diabetes mellitus, Parkinson's disease)
* Existing ocular conditions (e.g., retinal disease, cataracts, ptosis) or systemic/neurodevelopmental conditions (e.g., Down syndrome) which may influence refractive development
* Any condition that in the judgement of the investigator could potentially influence refractive development.
* Existing conditions that may affect the long-term health of the eye or require regular pharmacologic treatment that may adversely interact with study medication (e.g., JIA, glaucoma, diabetes mellitus, pre-diabetes)
* Inability to comprehend and/or perform any study-related clinical tests
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.